Amgen, Allergan launch cancer biosimilars in the US: 4 things to know

Amgen and Allergan have launched their biosimilar competitors to two of Roche’s top-selling cancer drugs in the U.S., according to PharmaPhorum.

Advertisement

Four things to know:

1. The companies said that the initial list price for the two drugs will be 15 percent lower than the price of their reference product.  

2. Amgen launched Mvasi, a biosimilar to Avastin. It will be available at a wholesale cost of $677.4 per 100 milligrams  and $2,709.60 for a single-dose vial. 

3. Allergan has launched Kanjiti, a biosimilar to Herceptin. It will be available at $3,697.26 per 420-milligram vial.

4. Herceptin and Avastin together brought in sales of $5.8 billion in 2018 for Roche.

Read the full report here

More articles on pharmacy:
Oklahoma opioid trial wraps: 10 takeaways
Drugmaker tried to shred records before FDA inspection, agency claims
Publix Pharmacy to deliver prescriptions to patients before hospital discharge

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, Colibri Healthcare

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.